Sugi Predict

Sugi Predict / Compounds / SCHEMBL4473335

SCHEMBL4473335

SCHEMBL4473335

C=Cc1sc2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 0.77
▸ TEK Q02763 10/20 0.77
▸ KIT P10721 9/20 0.77
▸ FLT1 P17948 8/20 0.77
▸ CSF1R P07333 6/20 0.77
▸ FLT4 P35916 6/20 0.77
▸ LCK P06239 5/20 0.77
▸ FGFR1 P11362 5/20 0.77
▸ FLT3 P36888 5/20 0.77
▸ FGFR3 P22607 4/20 0.77
▸ PDGFRB P09619 2/20 0.77
▸ PDGFRA P16234 2/20 0.77
▸ FGFR2 P21802 1/20 0.77
▸ FGFR4 P22455 1/20 0.77
▸ AURKA O14965 5/20 0.67
▸ GSK3B P49841 5/20 0.67
▸ LYN P07948 4/20 0.67
▸ EPHA2 P29317 4/20 0.67
▸ BLK P51451 4/20 0.67
▸ RPS6KA3 P51812 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091024 0.87 KDR (0.76) KDRTEKKITFLT1CSF1R
SCHEMBL6092489 0.87 KDR (0.81) KDRTEKKITFLT1CSF1R
SCHEMBL4466103 0.87 KDR (1.00) KDRTEKKITFLT1CSF1R
SCHEMBL4473239 0.84 KDR (0.76) KDRTEKKITFLT1CSF1R
SCHEMBL4477336 0.83 KDR (0.74) KDRTEKKITFLT1CSF1R
SCHEMBL4477355 0.82 KDR (0.74) KDRTEKKITFLT1CSF1R
SCHEMBL4472940 0.82 KDR (0.74) KDRTEKKITFLT1CSF1R
SCHEMBL4488148 0.81 KDR (0.73) KDRTEKKITFLT1CSF1R
SCHEMBL4470700 0.80 KDR (0.72) KDRTEKKITFLT1CSF1R
SCHEMBL4490533 0.80 KDR (0.72) KDRTEKKITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885TEK 324/4885KIT 361/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.